Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval
Reimbursement Challenges
Executive Summary
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.
You may also be interested in...
Agios CEO Fouse On Building A Sustainable Business Model
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark
Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming and new updates from multiple Asian companies.